Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 3
2017 6
2018 7
2019 5
2020 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Ventricular arrhythmias and sudden death events following acalabrutinib initiation.
Bhat SA, Gambril J, Azali L, Chen ST, Rosen L, Palettas M, Wiczer TE, Kalathoor S, Zhao Q, Rogers KA, Kittai A, Grever M, Awan F, Ruz P, Byrd JC, Woyach J, Addison D. Bhat SA, et al. Blood. 2022 Nov 17;140(20):2142-2145. doi: 10.1182/blood.2022016953. Blood. 2022. PMID: 35917449 Free PMC article.
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Byrd JC, et al. Clin Cancer Res. 2020 Aug 1;26(15):3918-3927. doi: 10.1158/1078-0432.CCR-19-2856. Epub 2020 Mar 24. Clin Cancer Res. 2020. PMID: 32209572 Free PMC article. Clinical Trial.
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Woyach JA, Blachly JS, Rogers KA, Bhat SA, Jianfar M, Lozanski G, Weiss DM, Andersen BL, Gulrajani M, Frigault MM, Hamdy A, Izumi R, Munugalavadla V, Quah C, Wang MH, Byrd JC. Woyach JA, et al. Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 Jan 8. Cancer Discov. 2020. PMID: 31915195 Free PMC article. Clinical Trial.
Hypertension and incident cardiovascular events following ibrutinib initiation.
Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhat S, Byrd JC, Woyach JA, Awan F, Addison D. Dickerson T, et al. Blood. 2019 Nov 28;134(22):1919-1928. doi: 10.1182/blood.2019000840. Blood. 2019. PMID: 31582362 Free PMC article. Clinical Trial.
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.
Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, Guerrero T, Levine LB, Lucas F, Shindiapina P, Sigmund AM, Sullivan M, Wiczer TE, Woyach JA, Awan FT. Rogers KA, et al. Leukemia. 2019 Oct;33(10):2527-2530. doi: 10.1038/s41375-019-0481-1. Epub 2019 May 13. Leukemia. 2019. PMID: 31086260 Free PMC article. No abstract available.
26 results